Guardant Health Receives Expanded Medicare Coverage

 

• Blood test for minimal residual disease (MRD) now covered to monitor for disease recurrence after curative intent treatment
• Tissue-free approach addresses need for cancer patients who have no tissue available or for whom tissue specimens are difficult to obtain

https://www.businesswire.com/news/home/20250121632281/en/